title: Infliximab dose and charge escalation patterns in managed care.
authors.affiliation: Evidence-Based Medicine, Zynx Health, Beverly Hills, California 90212, USA. dgeorge@cerner.com
authors.forename: Dorothy
authors.initials: D
authors.lastname: George
authors.forename: Pam
authors.initials: P
authors.lastname: Kadlubek
authors.forename: Deepika
authors.initials: D
authors.lastname: Batra
authors.forename: George
authors.initials: G
authors.lastname: Goldberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000191:economics* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D016527:Drug Costs / Q000639:trends*; D005260:Female; D006302:Health Services Research; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D000069285:Infliximab; D008297:Male; D008329:Managed Care Programs / Q000458:organization & administration*; D008875:Middle Aged; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D000069285:Infliximab